Amphastar Pharmaceuticals Files 8-K

TL;DR

AMPH filed an 8-K on May 7th, likely covering financial results.

AI Summary

On May 7, 2025, Amphastar Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or new material events were detailed in the provided excerpt.

Why It Matters

This filing indicates Amphastar Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is standard practice for public companies.

Risk Assessment

Risk Level: low — This is a routine SEC filing reporting financial information and exhibits, with no immediate indication of significant new risks.

Key Players & Entities

• Amphastar Pharmaceuticals, Inc. (company) — Registrant
• May 7, 2025 (date) — Report Date
• 0001297184-25-000025 (filing_id) — Accession Number

FAQ

From the Filing

0001297184-25-000025.txt : 20250507 0001297184-25-000025.hdr.sgml : 20250507 20250507162310 ACCESSION NUMBER: 0001297184-25-000025 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250507 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250507 DATE AS OF CHANGE: 20250507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Amphastar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001297184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 330702205 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36509 FILM NUMBER: 25921793 BUSINESS ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 909-980-9484 MAIL ADDRESS: STREET 1: 11570 SIXTH STREET CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 8-K 1 amph-20250507x8k.htm 8-K 0001297184 false 0001297184 2025-05-07 2025-05-07 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ​ Da t e of Re port (Da t e of ea rli e st e v e nt Re port e d ) : May 7, 2025 ​ Amphastar Pharmaceuticals, Inc. (E x a ct Na m e of Re gistr a nt a s S p e cifi e d in C h a rt e r ) ​ ​ ​ ​ Delaware 001-36509 33-0702205 (S t a t e or O th e r Jurisdiction of I ncorpor a tion ) (Commission File N umb e r ) (I.R.S. Employer I d e ntific a tion N umb e r ) ​ ​ ​ 11570 6th Street ​ Rancho Cucamonga , California 91730 ( Addr e ss of Principal E x e cutiv e O ffic e s ) (Z ip C od e) ​ Re gistr a nt's t e l e phon e numb e r , including a r ea cod e : ( 909 ) 980-9484 ​ C h e ck the a ppropri a t e box b e low if the F orm 8- K filing is int e nd e d to simultaneously s a tisfy the filing oblig a tion of the r e gistr a nt und e r a ny of the following provisions: ​ ☐ Written communications pursu a nt to R ul e 425 und e r the Securities Act (17 CFR 230.425) ☐ S oliciting ma t e ri a l pursu a nt to R ul e 14a-12 und e r the Exchange Act (17 CFR 240.14a-12) ☐ P r e- commencement communications pursu a nt to R ul e 14 d -2( b ) und e r the Exchange Act (17 CFR 240.14 d -2( b )) ☐ P r e- commencement communications pursu a nt to R ul e 13e-4( c ) und e r the Exchange Act (17 CFR 240.13e-4( c )) ​ Securities registered pursuant to Section 12(b) of the Act: ​ T ​ ​ ​ ​ ​ ​ Title of each class ​ Trading Symbol(s) ​ Name of each exchange on which registered ​ ​ ​ ​ Common Stock, par value $0.0001 per share ​ AMPH ​ The NASDAQ Stock Market LLC ​ ​ ​ ​ ​ ​ ​ ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( § 240.12b-2 of this chapter). ​ Emerging growth company ☐ ​ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻ ​ ​ ​ ​ Item 2.02. Results of Operations and Financial Condition. ​ On May 7, 2025, Amphastar Pharmaceuticals, Inc. issued a press release announcing its financial results for the three months ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. ​ The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange A